文献速递衰弱、肌少症与跌倒老年慢病共病管理

中年期全身性炎症与晚年衰弱相关:ARIC研究

Midlife Systemic Inflammation Is Associated With Frailty in Later Life: The ARIC Study.
PubMed 文献 · J Gerontol A Biol Sci Med Sci · 2019-01-01

基于社区动脉粥样硬化风险研究(ARIC),在5760名参与者中分析中年期炎症标志物与晚年衰弱的关联。结果显示,中年期炎症综合评分每升高1个标准差,24年后衰弱风险增加(OR=1.39,95%CI:1.18-1.65),且CRP持续升高者晚年更易符合衰弱标准。

要点

  • 中年期炎症综合评分每升高1个标准差,24年后衰弱风险增加39%。
  • CRP每升高1个标准差,21年和15年后衰弱风险分别增加24%和35%。
  • CRP持续≥3 mg/L或转为升高者,晚年更易符合衰弱标准。

核心结论

  • 中年期全身性炎症可能独立促进部分人群晚年衰弱的病理生理变化。

研究设计与样本

  • 基于社区的前瞻性队列研究,纳入5760名参与者,中年期(平均52岁)测量炎症标志物,晚年(平均75岁)评估衰弱。

主要发现

  • 中年期炎症综合评分每升高1个标准差,24年后衰弱风险增加(OR=1.39,95%CI:1.18-1.65)。
  • Visit 2 CRP每升高1个标准差,21年后衰弱风险增加(OR=1.24,95%CI:1.09-1.40)。
  • Visit 4 CRP每升高1个标准差,15年后衰弱风险增加(OR=1.35,95%CI:1.19-1.53)。
  • CRP持续≥3 mg/L或转为升高者,晚年更易符合衰弱标准。

关键数值与推荐

  • 炎症综合评分由纤维蛋白原、血管性血友病因子、因子VIII和白细胞计数标准化后合并。
  • CRP持续升高定义为Visit 2和Visit 4均≥3 mg/L。

临床怎么用

  • 对中年期炎症标志物升高者,应关注晚年衰弱风险,加强随访和综合评估。

局限性

  • 关联在白人与非洲裔参与者间存在差异,外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Evidence suggests that systemic inflammation may have a mechanistic role in age-related frailty, yet prospective data is limited. We examined whether systemic inflammation during midlife was associated with late-life frailty within the community-based Atherosclerosis Risk in Communities Study. METHODS: Plasma levels of four inflammatory markers (fibrinogen, von Willebrand factor, and Factor VIII, and white blood cell count) were measured during Visit 1 (1987-1989; mean age: 52 [5]), standardized into z-scores, and combined to create an inflammation composite score. High-sensitivity C-reactive protein (CRP) was measured 3 (Visit 2, 1990-1992) and 9 (Visit 4, 1996-1999) years later. Frailty was evaluated in 5,760 participants during late life (Visit 5, 2011-2013; mean age: 75 [5]). Analyses were adjusted for demographic and physiological variables, and midlife medical comorbidity using logistic regression. RESULTS: A 1 SD increase in midlife inflammation composite score was associated with higher odds of frailty 24 years later (odds ratio [OR] = 1.39, 95% confidence interval [CI]: 1.18-1.65). Similarly, each standard deviation increase in Visit 2 CRP (OR = 1.24, 95% CI: 1.09-1.40) and Visit 4 CRP (OR = 1.35, 95% CI: 1.19-1.53) was associated with a higher odds of frailty 21 and 15 years later. Participants who maintained elevated CRP (≥3 mg/L) at Visits 2 and 4 or transitioned to a state of elevated CRP during this period were more likely to subsequently meet frailty criteria compared to those who maintained low CRP. These associations were stronger among white, compared to African American, participants (p-interactions < .038). CONCLUSIONS: Systemic inflammation during midlife may independently promote pathophysiological changes underlying frailty in a subset of the population.

来源:J Gerontol A Biol Sci Med Sci,查看原文。版权归原作者所有。

引用

  1. Walker KA, Walston J, Gottesman RF, et al. Midlife Systemic Inflammation Is Associated With Frailty in Later Life: The ARIC Study. J Gerontol A Biol Sci Med Sci. 2019. PMID: 29534173. doi:10.1093/gerona/gly045

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。